Omeros Co. (NASDAQ:OMER) Shares Purchased by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. lifted its position in Omeros Co. (NASDAQ:OMER) by 4.0% in the 3rd quarter, Holdings Channel.com reports. The fund owned 485,035 shares of the biopharmaceutical company’s stock after acquiring an additional 18,454 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Omeros were worth $1,926,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in OMER. SPC Financial Inc. acquired a new position in shares of Omeros in the 3rd quarter valued at about $77,000. SG Americas Securities LLC bought a new position in Omeros in the third quarter worth about $80,000. AQR Capital Management LLC acquired a new position in Omeros in the second quarter valued at approximately $105,000. Rhumbline Advisers grew its holdings in shares of Omeros by 6.1% during the second quarter. Rhumbline Advisers now owns 111,778 shares of the biopharmaceutical company’s stock valued at $454,000 after purchasing an additional 6,435 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its position in shares of Omeros by 16.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 218,580 shares of the biopharmaceutical company’s stock worth $887,000 after purchasing an additional 31,081 shares during the period. 48.79% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

OMER has been the subject of a number of analyst reports. Rodman & Renshaw initiated coverage on Omeros in a research report on Thursday, November 14th. They set a “buy” rating and a $9.00 price objective for the company. RODMAN&RENSHAW raised shares of Omeros to a “strong-buy” rating in a report on Thursday, November 14th. Cantor Fitzgerald restated a “neutral” rating on shares of Omeros in a research report on Thursday, November 14th. StockNews.com upgraded shares of Omeros from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. Finally, Needham & Company LLC restated a “hold” rating on shares of Omeros in a research report on Thursday, November 14th. Three investment analysts have rated the stock with a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $9.00.

Omeros Stock Performance

Shares of OMER stock opened at $7.59 on Tuesday. Omeros Co. has a 1 year low of $2.61 and a 1 year high of $12.65. The stock has a fifty day moving average of $6.68 and a two-hundred day moving average of $5.05. The firm has a market capitalization of $439.84 million, a PE ratio of -3.29 and a beta of 1.97.

Omeros Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.